📊 CNBX Key Takeaways
Is CNBX Pharmaceuticals Inc. (CNBX) a Good Investment?
CNBX is in severe financial distress with negative stockholders' equity of -$2.6M, liabilities exceeding assets, and virtually no revenue generation. The company is burning cash with -$47.4K operating cash flow and has negligible liquid assets of $7.7K, indicating imminent solvency risk.
CNBX Pharmaceuticals shows extremely weak fundamentals: no revenue, recurring operating and free cash flow losses, minimal cash, and deeply negative stockholders' equity. While the latest period shows a narrower net loss, the improvement is low quality without any demonstrated commercial traction, leaving financial health highly stressed and the business dependent on external funding.
Why Buy CNBX Pharmaceuticals Inc. Stock? CNBX Key Strengths
- Minimal capital expenditure suggests no major cash drains from asset purchases
- Some form of continued operations despite extreme financial stress
- Extremely low absolute debt levels relative to industry
- Net loss improved year over year, indicating some expense reduction
- Operating cash burn is modest in absolute dollar terms
- Capital expenditure requirements are currently minimal
CNBX Stock Risks: CNBX Pharmaceuticals Inc. Investment Risks
- Negative stockholders' equity indicates technical insolvency and balance sheet impairment
- Zero revenue generation with no meaningful profitability pathway visible
- Severe liquidity crisis with current ratio of 0.00 and only $7.7K cash against $586.2K liabilities
- Negative operating cash flow of -$47.4K indicates ongoing cash burn
- No insider confidence demonstrated by absence of Form 4 filings in last 90 days
- Negative ROA of -1018.8% shows extreme asset value destruction
- Zero revenue means the business has no proven operating model or commercial traction
- Negative equity and a near-zero current ratio indicate severe balance sheet and liquidity stress
- Very low cash relative to liabilities raises substantial going-concern and dilution risk
Key Metrics to Watch
- Stockholders equity trajectory - recovery toward positive is critical
- Operating cash flow trend - must return to positive sustainability
- Revenue generation initiatives - any meaningful revenue would be positive signal
- Cash burn rate and runway - how long until cash depletion at current burn rate
- Debt restructuring or capital injection announcements
- Quarterly revenue generation or other evidence of sustained commercial progress
- Cash balance versus operating cash burn and total liabilities
CNBX Pharmaceuticals Inc. (CNBX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CNBX Profit Margin, ROE & Profitability Analysis
CNBX vs Healthcare Sector: How CNBX Pharmaceuticals Inc. Compares
How CNBX Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CNBX Pharmaceuticals Inc. Stock Overvalued? CNBX Valuation Analysis 2026
Based on fundamental analysis, CNBX Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CNBX Pharmaceuticals Inc. Balance Sheet: CNBX Debt, Cash & Liquidity
CNBX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CNBX Pharmaceuticals Inc.'s revenue has grown significantly by 1,221% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
CNBX Revenue Growth, EPS Growth & YoY Performance
CNBX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | N/A | -$44.1K | $0.00 |
| Q1 2026 | N/A | -$34.4K | $0.00 |
| Q3 2025 | N/A | -$59.7K | $0.00 |
| Q2 2025 | N/A | -$69.8K | $0.00 |
| Q1 2025 | N/A | -$34.4K | $0.00 |
| Q2 2024 | N/A | -$325.5K | $-0.01 |
| Q1 2024 | N/A | -$178.5K | $0.00 |
| Q3 2023 | N/A | -$154.7K | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CNBX Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
CNBX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CNBX Pharmaceuticals Inc. (CIK: 0001343009)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CNBX
What is the AI rating for CNBX?
CNBX Pharmaceuticals Inc. (CNBX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CNBX's key strengths?
Claude: Minimal capital expenditure suggests no major cash drains from asset purchases. Some form of continued operations despite extreme financial stress. ChatGPT: Net loss improved year over year, indicating some expense reduction. Operating cash burn is modest in absolute dollar terms.
What are the risks of investing in CNBX?
Claude: Negative stockholders' equity indicates technical insolvency and balance sheet impairment. Zero revenue generation with no meaningful profitability pathway visible. ChatGPT: Zero revenue means the business has no proven operating model or commercial traction. Negative equity and a near-zero current ratio indicate severe balance sheet and liquidity stress.
What is CNBX's revenue and growth?
CNBX Pharmaceuticals Inc. reported revenue of $0.0.
Does CNBX pay dividends?
CNBX Pharmaceuticals Inc. does not currently pay dividends.
Where can I find CNBX SEC filings?
Official SEC filings for CNBX Pharmaceuticals Inc. (CIK: 0001343009) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CNBX's EPS?
CNBX Pharmaceuticals Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CNBX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, CNBX Pharmaceuticals Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CNBX stock overvalued or undervalued?
Valuation metrics for CNBX: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CNBX stock in 2026?
Our dual AI analysis gives CNBX Pharmaceuticals Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CNBX's free cash flow?
CNBX Pharmaceuticals Inc.'s operating cash flow is $-47.4K, with capital expenditures of $0.0.
How does CNBX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.00 (avg: 2).